Autoimmune disorders, rheumatoid arthritis, systemic inflammation, and immune dysregulation
330 articles
A landmark 48-RCT Cochrane review finds high-certainty evidence that convalescent plasma does not reduce death in moderate-to-severe COVID-19.
A runaway immune response — not the pathogen itself — drives citrus greening disease, echoing autoimmune mechanisms seen in human illness.
A completed Phase 3 trial tests placental MSC secretome injections against placebo in 60 GvHD patients at an Iranian hospital.
A new review reveals how cellular crosstalk, non-coding RNAs, and lung microbiota drive pulmonary fibrosis — and where treatments may break through.
Scientists mapped key attack sites on measles virus proteins, finding human antibodies that powerfully neutralize MeV before and after exposure.
A novel biologic targeting IL-33 shows promising advances in COPD treatment, potentially reshaping how chronic lung disease is managed.
A new NEJM case report documents a human infection with highly pathogenic avian influenza A(H5N5), a subtype rarely reported in humans, raising pandemic preparedness concerns.
With no approved vaccine for hantavirus, experts warn the world is dangerously unprepared for future outbreaks of this deadly rodent-borne disease.
A murine arthritis study finds rapamycin suppresses neuropeptide Y, linking cellular senescence to joint inflammation via SASP cytokines.
Demethyleneberberine, derived from traditional Chinese medicine, significantly reduced lung scarring by targeting NLRP3 inflammasome and EMT in mice.
Structural biology uncovers the exact amino acid motif causing species-specific drug failures, enabling transgenic mouse models for better P2X7 drug testing.
Senescent cells drive cyst growth in ADPKD, and targeting them with senolytics or the aldose reductase inhibitor epalrestat delays disease progression.
